HealthQuill genetic research
Regeneron Pharmaceuticals, Inc. plans to buy most of the assets of the bankrupt genetics and biotechnology company, 23andMe Holding, for $256 million.
Drugs Medical Pharma

Regeneron to buy bankrupt 23andMe Holding assets for $256 million

HQ Team May 20, 2025: Regeneron Pharmaceuticals, Inc. plans to buy most of the assets of the bankrupt genetics and biotechnology company, 23andMe.

Read More
Novartis AG, the world's fourth-largest pharmaceutical company by revenue, announced its Kisqali drug reduced breast cancer recurrence when diagnosed at an early stage and has stopped its ongoing trial.
Health Pharma

New study finds some healthy breast cells may harbor cancer cells

Bharti Jayshankar November 30, 2024: A study done by the Ā University of Texas MD Anderson Cancer CenterĀ revealed that some breast cells in healthy.

Read More